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meable form of α-syn (TAT-α-syn) and to 6-OHDA. Intrastria-
tally administered TAT-DJ-1 reduced 6-OHDA toxicity in vivo 
in C57BL/6 mice. Finally, when we injected TAT-α-syn (A30P) 
in the striatum of DJ-1 (–/–) animals, dopamine was depleted 
more than in the control strain.  Conclusion: DJ-1 appears to 
have a protective role against dopaminergic degeneration 
triggered by α-syn or 6-OHDA, reinforcing the possible thera-
peutic importance of this protein in PD.  © 2014 S. Karger AG, Basel 
 Introduction 
 Parkinson’s disease (PD) is a common neurodegenera-
tive movement disorder and a major challenge on account 
of the lack of therapies, which in addition to attenuating 
symptoms should also prevent neurodegeneration  [1, 2] . 
The neurochemical basis relies on the depletion of dopa-
mine (DA) in the striatum, due to the neurodegeneration of 
striatum-projecting dopaminergic neurons in the substan-
tia nigra. Almost all PD cases are sporadic, only in a minor 
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 Abstract 
 Background: Dopaminergic degeneration is a major finding 
in brains of patients with Parkinson’s disease (PD), together 
with Lewy bodies, intraneuronal inclusions mainly composed 
of the fibrillogenic protein α-synuclein (α-syn). The familial-
PD-related protein DJ-1 was reported to reduce dopaminer-
gic degeneration triggered by α-syn or by the dopaminergic-
selective neurotoxin 6-hydroxydopamine (6-OHDA).  Objec-
tive: The aim was to further investigate the role of DJ-1 in 
dopaminergic degeneration and to see whether a cell-per-
meable recombinant form of DJ-1 (TAT-DJ-1) could restore 
dopamine depletion in vivo, thus representing an innovative 
therapeutic approach.  Methods: We developed in vitro 
(PC12/TetOn cells and mouse primary mesencephalic neu-
rons) and in vivo models [including DJ-1 knockout (–/–) mice] 
to investigate DJ-1 in dopaminergic degeneration.  Results: 
We found that in PC12/TetOn cells overexpressing α-syn with 
the familial-PD linked mutation A30P, DJ-1 silencing in-
creased α-syn (A30P) toxicity. Primary mesencephalic neu-
rons from DJ-1 (–/–) mice were more vulnerable to a cell-per-
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fraction (around 5%) has a genetic alteration been seen in a 
group of genes linked to rare familial forms and coding for 
proteins with no apparent functional interactions  [3–5] . 
Consequently, a major question is the relationship between 
these proteins, whose changes lead ultimately to a similar 
pathology. Single-point mutations or multiplications of the 
gene PARK-1 [alias α-synuclein (α-syn); GenBank: NM_ 
000345; OMIM: No. 168600] and single-point mutations or 
deletions of the PARK-7 gene (alias DJ-1; GenBank: NM_ 
007262; OMIM: No. 606324) cause an autosomal dominant 
and an autosomal recessive form of familial PD, respective-
ly  [6–9] . α-syn aggregates are present in Lewy bodies, a PD 
hallmark  [10] . An α-syn-dependent etiopathological hy-
pothesis states that in PD α-syn aggregates and gains a toxic 
function that seems related to its oligomeric state  [11, 12] . 
Transgenic models developed to support this hypothesis re-
sulted in mild to severe phenotypes  [13, 14] . Confirming the 
importance of α-syn dosage in the development of PD, 
PARK-1 triplication has been associated with familial PD 
 [15, 16] . The physiological function of α-syn is not clear, 
though some α-syn neuroprotective features that deal with 
chaperone-like activity, DA homeostasis and correct synap-
tic vesicular trafficking have been described  [17–20] .
 DJ-1 mutations are rare single-nucleotide substitutions 
or deletions leading to a nonfunctional protein  [21–24] . 
DJ-1 function in the nervous system deals with antioxidant 
activity  [25, 26] , chaperone-like properties  [27, 28] , mito-
chondrial physiology  [29, 30] and DA homeostasis  [31, 32] .
 The interaction between α-syn and DJ-1 has been ex-
plored in cell models of α-syn overexpression, suggesting 
that DJ-1 is involved in preventing α-syn toxicity by 
 upregulating HSP70 gene transcription (GenBank 
NM_005345)  [33] , which prevented α-syn toxicity in vivo 
and in vitro  [34, 35] . As no fully satisfactory genetic mod-
el of PD is available, the toxin 6-hydroxydopamine (6-
OHDA), both in vitro and in vivo, is widely used to re-
produce dopaminergic degeneration for experimental 
purposes  [36] . We set out to further clarify the impor-
tance of DJ-1 for the neurodegeneration triggered by 
α-syn or 6-OHDA in independent cellular and animal 
models, including  PARK-7 null mice (DJ-1 –/–).
 Materials and Methods 
 PC12/TetOn (α-syn) Cell Lines 
 PC12/TetOn cell lines were prepared as described  [37] . Cells 
were cultured on disposable plasticware coated with poly- D -lysine 
at 37   °   C, 5% CO 2 in RPMI-1640 medium (Invitrogen, Carlsbad, 
Calif., USA) supplemented with 10% tetracycline-free horse se-
rum, 5% fetal calf serum (Sigma Aldrich, St. Louis, Mo., USA), 
2 m M  L -glutamine, 100 UI/ml penicillin and 100 mg/ml streptomy-
cin (Invitrogen). To start α-syn expression, freshly prepared doxy-
cycline was added to the culture medium (range: 0.1–1 μg/ml).
 Primary Mesencephalic Culture 
 Brain tissue was removed from fetal mice on embryonic day 13 
and the mesencephalic region isolated under a stereotactic micro-
scope. After tissue dissociation, the cells were plated (50,000 cells/
cm 2 ) in 8-well chamber slides (Thermo Fisher Scientific, Waltham, 
Mass., USA) precoated with poly- D -lysine in Dulbecco’s minimal 
essential medium supplemented with 2% B27, 1% fetal bovine se-
rum, 2 m M  L -glutamine, 100 IU/ml penicillin, 100 μg/ml streptomy-
cin and 1 μ M cytosine arabinoside (Invitrogen). Cultures were kept 
at 37   °   C in a humidified 5% CO 2 atmosphere for 7 days before the 
experiment.
 DJ-1 Cloning and TAT-Fused Protein Generation 
 Human DJ-1 full-length cDNA was cloned starting from a 
 human brain cDNA library (Clontech, Palo Alto, Calif., USA) by 
rapid amplification of cDNA end PCR. The amplified cDNAs 
were then cloned into pRSET expression vectors (Invitrogen) and 
fully sequenced. To generate the fusion proteins TAT-DJ-1, the 
sequence coding for a peptide containing the translocation do-
main of the HIV-1 protein TAT (underlined) and a 6XHis-tag 
( MRGSHHHHHHGMARG YGRKKRR PASPGAS) was inserted 
in frame before the N terminus of the corresponding cDNA. The 
fusion protein was then expressed and purified using standard re-
combinant techniques  [38] . The TAT-fused form of α-syn (A30P) 
and the TAT-fused form of green fluorescent protein (TAT-GFP) 
were purified as described  [39, 40] .
 6-OHDA Challenge and TAT-Fused Protein Treatment 
 To challenge cells with 6-OHDA, 60 × 10 3 PC12/TetOn cells 
were seeded in a 96-well plate and incubated overnight. The next 
day, the medium was changed, a freshly prepared 6-OHDA dilution 
was added (final concentration 50 μ M ), and the cells were incubated 
for 24 h. Viable cells were counted by the methylthiazolyl tetrazo-
lium (MTT) colorimetric assay (Promega, Madison, Wisc., USA).
 As for primary mesencephalic neurons, starting from the 8-well 
chamber slide culture described above, we exposed cells to increas-
ing doses of 6-OHDA (10–100 μ M ) for 24 h, then cells were fixed 
and the number of neuronal cells/well was assessed by neuronal nu-
clear antigen (NeuN) immunocytochemistry. The number of tyro-
sine hydroxylase (TH)-positive neurons was counted in the same 
well and the TH-positive/NeuN-positive percentage was calculated.
 When mesencephalic neurons were challenged with TAT-α-
syn (wild-type, WT, or A30P), cells were seeded as previously de-
scribed and exposed for 72 h to increasing amounts of the recom-
binant proteins (10, 50, 100 μ M )  [41] . Viability was then measured 
by TH-positive/NeuN-positive cell percentage as just described.
 RNA Interference 
 RNA interference was tested as follows: 80 × 10 3 PC12/TetOn 
cells were seeded in a 24-well plate and grown overnight. The next 
day, the medium was replaced with 250 μl of fresh complete medi-
um,  and 2 predesigned double-stranded small-interfering RNAs 
(siRNAs) against the DJ-1 mRNA sequence (siRNA-A sense: 5 ′ - 
GGGACC AUAUGAUGUGGUGtt-3 ′ ; antisense: 5 ′ -CACCACAUC 
AUAUG GUCCCtc-3 ′ ; siRNA-B sense: 5 ′ -GGAGCAGGAAAAC 
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Ambion, Austin, Tex., USA) were added independently in 50 μl se-
rum-free Optimem (Invitrogen) at 100 n M final concentration using 
as vehicle SilentFect liposome formulation (BioRad Laboratories, 
Hercules, Calif., USA) for 24–96 h, without any other  medium change, 
to downregulate DJ-1. To prove specific DJ-1 silencing, a negative 
control siRNA was used (CT–), comprising a 19-bp scrambled se-
quence with 3 ′ -dT overhangs that has no significant homology to 
any known human gene sequence (Ambion). Cell viability was then 
assessed by the MTT assay, or cells were lysed in the presence of a 
wide-range protease inhibitor to obtain a total protein extract.
 Western Blotting and Slot Blot 
 Proteins were denatured by heating for 5 min at 95  °  C in Laem-
mli sample buffer twice, briefly spun and about 25 μg of total pro-
tein extract was run on sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (12%) and transferred to a nitrocellulose mem-
brane (BioRad). The membrane was incubated overnight with a 
primary antibody, for 1 h with a horseradish peroxidase-conjugat-
ed secondary antibody (Santa Cruz Biotechnology, Santa Cruz, Ca-
lif., USA) and the detection was done with Immobilon Western 
Chemiluminescent HRP substrate (luminal; Millipore Corpora-
tion, Billerica, Mass., USA). Signals were quantified by densitom-
etry, using National Institutes of Health software (ImageJ). Slot blot 
for α-syn aggregate detection was performed as described  [37] .
 Immunocytochemistry 
 Primary mesencephalic cells were cultured on 8-well plastic 
chamber slides (Thermo Fisher Scientific) for 7 days before the as-
say. Cells were then fixed with 4% paraformaldehyde (Merck, 
 Germany) and permeabilized using 0.5% Triton X-100, 0.2% fetal 
calf serum in phosphate-buffered saline (PBS). Then, they were 
incubated overnight at 4   °  C with a primary antibody in PBS + 1% 
horse serum, followed by a Cy3- or Cy5-conjugated secondary an-
tibody (Jackson Immuno Laboratories, West Grove, Pa., USA) di-
luted 1:  200 in PBS + 1% horse serum. Cells were then analyzed 
with a fluorescence microscope coupled to a digital camera (Olym-
pus Corporation, Tokyo, Japan).
 Animal Surgery and Ethics 
 Nine-week-old male C57BL/6 mice (Charles River, Italy) or 
matched PARK7 null mice (DJ-1 –/–; http://jaxmice.jax.org/
strain/006577.html, The Jackson Laboratory, Bar Harbor, Me., 
USA) were used. They were housed in groups of 5 in a sound-proof 
room until surgery, after which they were housed singly until the 
end of the experiment. Mice were maintained on a 12-hour light/
dark cycle (lights on from 7.00 a.m. to 7.00 p.m.), at a constant 
temperature of 21 ± 1   °   C and 60% relative humidity with free ac-
cess to standard diet and tap water.
 Mice were anesthetized using avertin 2.5% (400 mg/kg, i.p.) 
and placed into a stereotactic frame adapted for mice (David Kopf 
Instruments, Tujunga, Calif., USA). 6-OHDA was dissolved at a 
concentration of 2 μg/μl in 0.2% ascorbic acid in saline, and 2 μl 
was injected at a rate of 0.5 μl/min in the left striatum. Control 
animals received the same volume of saline with 0.2% ascorbic 
acid. The needle was left in place for 5 min after the injection before 
retraction. The injection was done with a Hamilton syringe at 
the  following coordinates: AP +1 mm, L +2 mm, V  − 2.8 mm. 
6- OHDA-lesioned mice were sacrificed 10 days after treatment.
 To evaluate the protective role of TAT-DJ-1 against 6-OHDA, 
C57BL/6 mice were first implanted with a cannula in the striatum, 
injected with 4 μg of TAT-DJ-1 or recombinant DJ-1 (rDJ-1) on 
days –1, +1 and +4 (considering 6-OHDA administration as day 0) 
and sacrificed 10 days after the 6-OHDA injection (6 mice/group).
 For the treatment with TAT-α-syn (A30P), 2 μl of the recom-
binant protein (or of TAT-GFP as negative control) corresponding 
to increasing amounts (0.05–2.5 μg) were injected in the left stria-
tum as described above, and the mice were euthanized 10 days af-
ter the injection.
 Procedures involving animals and their care were conducted in 
conformity with the institutional guidelines at the IRCCS Institute 
for Pharmacological Research Mario Negri in compliance with na-
tional (Decreto Legge No. 116/92, Gazzetta Ufficiale, supplement 40, 
February 18, 1992; Circolare No. 8, Gazzetta Ufficiale, July 14, 1994) 
and international laws and policies (EEC Council Directive 86/609, 
OJL 358, 1, December 12, 1987; Guide for the Care and Use of Labo-
ratory Animals, US National Research Council, eighth edition, 2011).
 Striatal Dopamine Content 
 The mice were killed by cervical dislocation; the brains were 
rapidly removed and immediately placed in ice-cold saline. The 
right and left striata were then dissected on an ice-cold plastic dish. 
Tissue samples were weighed, transferred into 10 volumes of 0.1  M 
perchloric acid and homogenized by sonication (Branson Ultra-
sonic Corporation, Danbury, Conn., USA). Homogenates were 
left at 4  °  C for 30 min to complete deproteinization, and, after cen-
trifugation at 4,800  g for 10 min at 4  °  C, the supernatants were col-
lected for chromatographic assay. DA and serotonin (5-HT) tissue 
levels were measured by high-performance liquid chromatogra-
phy (HPLC) coupled to electrochemical detection, as detailed else-
where  [42] . Data were recorded and analyzed with a computer-
assisted data system (Azur, Datalys, France).
 Immunohistochemistry 
 After perfusion, the mouse whole brain was removed and 
transferred into 4% paraformaldehyde (Merck) at 4    °    C. After 
3–4 h, the brains were removed and left at 4  °  C in 30% sucrose and 
PBS solution and were cut into 30-μm coronal sections on a cryo-
stat (Leica, Germany). Free-floating sections were stained for TH 
(Chemicon International, Temecula, Calif., USA, 1: 1,000) and de-
tected by diaminobenzidine reaction (Sigma Aldrich).
 The quantitative assessment of TH-positive neurons was per-
formed essentially as described  [43] . Shortly, TH immunoreactive 
cell bodies were counted in 3 consecutive coronal sections by an 
operator blind to the treatment using a ×40 objective in the ipsilat-
eral and contralateral substantia nigra pars compacta . 
 Antibodies 
 The following primary antibodies were used to run immunob-
lotting or immunochemistry: anti-DJ-1 polyclonal antibody (dilu-
tion 1: 1,000; Santa Cruz Biotechnology); anti-α-tubulin monoclo-
nal antibody (dilution 1: 5,000; Abcam, Cambridge, UK), anti-
oligomer (A11) polyclonal antibody (dilution 1: 250; Invitrogen), 
anti-6XHis-tag mouse monoclonal antibody (1: 1,000; Abcam), 
anti-TH monoclonal antibody (dilution 1: 500; Chemicon Interna-
tional), anti-NeuN polyclonal antibody (dilution 1: 500; Abcam).
 Statistical Analysis 
 Statistics were analyzed with StatView version 5.0. One-way 
ANOVA (or 2-way ANOVA) was used, followed by Dunnett’s or 




















   
   
   
   
   
   
   
   
   
   
   



























 DJ-1 Silencing Affects α-syn (A30P) Toxicity in PC12/
TetOn Cells 
 To assess a relationship between DJ-1 and α-syn toxicity, 
we used siRNA technology to downregulate the DJ-1 level 
in PC12/TetOn cells, which overexpressed human α-syn 
(WT or mutated A30P) in a doxycycline-dependent induc-
ible way. First, we followed DJ-1 downregulation over time, 
starting from 24 to 96 h after siRNA treatment. Both PC12/
TetOn lines showed significant downregulation starting 
from 48 h, and the reduction was still evident at 96 h (data 
not shown). The best condition was siRNA 100 n M for 48 h 
( fig. 1 a, b). After that, we investigated the effect of DJ-1 si-
lencing in doxycycline-induced PC12/TetOn. Cells were 
first exposed for 48 h to DJ-1 siRNA, then induced with the 
antibiotic (0.1 or 1 μ M ) for a further 48 h. Cell viability was 
assessed by the MTT assay. For the DJ-1 silenced clone ex-
 Fig. 1. DJ-1 downregulation in PC12/TetOn discloses α-syn toxic-
ity.  a Western blotting showing DJ-1 downregulation by siRNA 
methodology in PC12/TetOn cells. The best condition was 100 n M 
siRNA for 48 h. Lipid vehicle is the control condition where cells 
were exposed to the transfecting agent only.  b Densitometric 
quantification of DJ-1 silencing. Values are the means ± standard 
deviation of 4 independent replicates;  * * *  p < 0.001, 1-way  ANOVA 
and Dunnett’s test.  c MTT assay assessing the effect of DJ-1 silenc-
ing in doxycycline-induced PC12/TetOn. Cells were exposed for 
48 h to DJ-1 siRNA and then induced with increasing doses of 
doxycycline for a further 48 h.  *  p < 0.05,  * *  p < 0.01, 2-way  ANOVA 
and Tukey’s post hoc test. CNT = Control (without doxycycline). 
 d Representative slot blot showing the effect of DJ-1 silencing on 
α-syn aggregation. PC12/TetOn cells were treated as just de-
scribed, and α-syn oligomeric species formation was assessed by 
A11 reactivity.  e Densitometric quantification of 3 independent 
replicates, performed by normalizing the A11 signal to α-tubulin 
immunoreactivity in the same blots (data not shown);  *   p < 0.05, 







































































   
   
   
   
   
   
   
   
   
   
   





















 DJ-1 and Dopaminergic Neuroprotection  Neurodegener Dis 2015;15:13–23 
DOI: 10.1159/000367993
17
pressing α-syn (A30P), we detected a doxycycline dose-de-
pendent decrease in cellular viability ( fig. 1 c). To verify if 
this reduction correlated with α-syn aggregation, we 
checked for oligomeric form generation with A11 antibody 
under doxycycline induction and DJ-1 silencing  [37] . We 
noticed an increase in the A11/α-tubulin ratio in the PC12/
TetOn line expressing α-syn (A30P;  fig. 1 d, e).
 Mesencephalic Neurons from DJ-1 (–/–) Mice Are 
More Susceptible to Both 6-OHDA and TAT-α-syn 
 To evaluate DJ-1’s neuroprotective role in a more phys-
iological model, we exposed mesencephalic primary neu-
rons prepared from DJ-1 (–/–) embryos to 6-OHDA for 
24 h. As shown in  figure 2 a, neurons from DJ-1 (–/–) mice 
were more susceptible to 6-OHDA toxicity than neurons 
from C57BL/6 control mice. The percentage of TH-posi-
tive neurons decreased in C57BL/6 cultures from 10 to 100 
μ M 6-OHDA but in DJ-1 (–/–) neurons the same 6-OHDA 
concentrations induced a greater mortality, which became 
significant in comparison to control mice from 50 μ M .
 Mesencephalic neurons were then exposed to the fu-
sion protein TAT-α-syn (WT) or TAT-α-syn (A30P). To 
confirm the TAT-α-syn-induced dopaminergic toxicity, 
we first did TH immunocytochemistry in treated cells. 
 Fig. 2. DJ-1 (–/–) mesencephalic primary neurons are more vul-
nerable than C57BL/6 neurons to 6-OHDA or TAT-α-syn. 
 a   Dose-response curve of 6-OHDA toxicity. Primary neurons 
were cultured as described in the Methods and challenged with 
increasing amounts of 6-OHDA.  *  p < 0.05, 2-way ANOVA and 
Tukey’s post hoc test.  b Immunocytochemistry for TH of mesen-
cephalic primary neurons from DJ-1 (–/–) mice, showing neuro-
degeneration after TAT-α-syn (WT) treatment. The arrows point 
to degenerated neurons with reduced harborization. A similar 
morphological response was evident in mesencephalic neurons 
from C57BL/6 control mice, or when we used TAT-α-syn (A30P) 
in both strains (data not shown). CNT = Control. Magnification 
×20.  c ,  d TAT-α-syn (WT) and TAT-α-syn (A30P) toxicity in 
C57BL/6 and DJ-1 (–/–) mesencephalic primary neurons. TAT-
α-syn was added to the medium after 7 days from culture start 
and, after a further 72 h, the number of TH-positive cells (TH+) 
was counted and expressed as percentage of NeuN-positive cells 
(NeuN+) in the same well.  *  p < 0.05,  * *  p < 0.01, 2-way ANOVA 
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After TAT-α-syn treatment, there were morphological 
signs of neuronal degeneration ( fig. 2 c). We move on vi-
ability assessment by TH-positive cell count. TH-positive 
neurons from DJ-1 (–/–) mice were more vulnerable to 
TAT-α-syn toxicity (both WT and mutated A30P) than 
TH-positive neurons from C57BL/6 mice ( fig. 2 c, d).
 TAT-DJ-1 Counteracts 6-OHDA Toxicity in vivo 
 To see whether DJ-1 was able to protect against dopa-
minergic degeneration in vivo, we treated C57BL/6 mice 
with the recombinant protein TAT-DJ-1 during 6-OHDA 
challenge. To verify the presence of the fusion protein at 
the striatal level, a first injection of TAT-DJ-1 was done 
and repeated after 48 h. Ten days after the second injec-
tion, the presence of the protein was detected by immu-
nohistochemistry using an antibody against its 6XHis-
tag. We found a positive and diffuse signal in the striatum, 
more marked than on the mock-injected contralateral 
side ( fig. 3 a).
 Having confirmed the bioavailability of TAT-DJ-1, we 
set up a neuroprotection experiment based on 2 distinct 
injections of TAT-DJ-1 as described above, 1 day before 
(day –1) and 1 after (day +1) the challenge with 6-OHDA. 
There was a significant protection of the TAT-DJ-1 pro-
tein ( fig. 3 b), measured as the inhibition of 6-OHDA-in-
duced striatal DA depletion 10 days after neurotoxin 
challenge; a recombinant form of DJ-1 without the TAT-
sequence (rDJ-1) gave no such protection in the same ex-
perimental setting ( fig. 3 b).
 To improve neuroprotection, we increased the num-
ber of TAT-DJ-1 injections. Mice were treated with TAT-
DJ-1 (or rDJ-1) 3 times, on days –1, +1 and +4 (consider-
ing the 6-OHDA injection as day 0). HPLC analysis of 
striatal DA 10 days after 6-OHDA challenge indicated a 
stronger neuroprotective effect of TAT-DJ-1 against 
6-OHDA, while rDJ-1 gave no protection ( fig. 3 c). Stria-
tal levels of 5-HT did not change, confirming the selective 
effect of 6-OHDA and TAT-DJ-1 treatment ( fig. 3 d).
 To support the rescue of dopaminergic system failure by 
TAT-DJ-1, we examined dopaminergic neurons in the sub-
stantia nigra by immunohistochemistry and TH-positive 
cell count. Compared with 6-OHDA-treated mice, TH im-
munoreactivity was greater in the 6-OHDA + TAT-DJ-1 
group, while in mice treated with rDJ-1 in the presence of 
the neurotoxin this effect was not evident. These results 
were confirmed by TH-positive cell count ( fig. 3 e, f).
 DJ-1 (–/–) Mice Have Greater DA Depletion after 
TAT-α-syn (A30P) 
 We set up an in vivo model of TAT-α-syn (A30P) tox-
icity in C57BL/6 mice. We injected the fusion protein 
(0.05–2.5 μg) in the left striatum, using as negative con-
trol a TAT-fused form of GFP, considering that a recom-
binant α-syn might have toxic effects also without the 
TAT-fused sequence  [44] . First, we verified that the TAT-
α-syn (A30P) protein was detectable at the striatal level 
10 days after injection. We were able to reveal a positive 
diffuse signal in the hemisphere lesioned with 2.5 μg of 
TAT-α-syn (A30P) using an antibody against its 6XHis-
tag ( fig. 4 a). Striatal tissues of TAT-α-syn (A30P)-treated 
mice were then collected for HPLC analysis of DA and 
5-HT levels ( fig. 4 b, c). We found a dose-dependent de-
pletion of DA in the TAT-α-syn (A30P)-treated animals, 
while 5-HT levels were unchanged. No difference in DA 
or 5-HT levels was detected in the TAT-GFP group (data 
not shown).
 TAT-α-syn (A30P) toxicity was confirmed by TH im-
munohistochemistry and TH-positive neuron count in the 
substantia nigra. The TAT-GFP group did not show any 
reduction in TH staining or TH-positive neuron count, but 
TAT-α-syn (A30P)-injected animals did ( fig. 4 d, e).
 Finally, we quantified the toxicity of TAT-α-syn 
(A30P) in DJ-1 (–/–) and C57BL/6 mice by comparing 
the DA levels in the two groups. DJ-1 (–/–) mice had 
about half the DA level of C57BL/6 animals treated with 
the same amount of TAT-α-syn (A30P; 2.5 μg;  fig. 4 f).
 Fig. 3. TAT-DJ-1 counteracts in vivo dopaminergic degeneration 
triggered by 6-OHDA.  a 6XHis-tag immunoreactivity. Picture 
showing the brain presence of TAT-DJ-1 10 days after its injec-
tion at the striatal level. The arrow points to the injection site. 
 b ,  c  C57BL/6 mice were lesioned with 6-OHDA (4 μg) in order 
to induce dopaminergic cell loss and DA depletion. To test the 
protective action of TAT-DJ-1, a group of animals was injected 
with the fusion protein twice ( b ) or 3 times ( c ), as described in 
the Methods. A different group received rDJ-1, together with 
6-OHDA.  *  p < 0.05,  * *  p < 0.01, 1-way ANOVA and Tukey’s post 
hoc test (6 mice/group).  d 5-HT levels referring to the experi-
ment in  c . Results are expressed as micrograms per gram of wet 
weight of striatum.  e TH immunoreactivity in the substantia nig-
ra: control group (vehicle alone); mice lesioned with 6-OHDA; 
mice treated with TAT-DJ-1 together with 6-OHDA; mice treat-
ed with rDJ-1 and 6-OHDA; mice injected with the recombinant 
proteins alone (TAT-DJ-1 or rDJ-1). In each picture, the dashed 
line separates the two brain hemispheres. The injection was al-
ways given into the hemisphere marked by the label, and the con-
tralateral one was used as control.  f Quantification of TH-posi-
tive (TH+) neuron number in the substantia nigra of mice receiv-
ing the treatment described in  e . Results are shown as direct 
count number.  * * *  p < 0.001, 1-way ANOVA and Tukey’s post 
hoc test (3 mice/group). 




















   
   
   
   
   
   
   
   
   
   
   















































































































































   
   
   
   
   
   
   
   
   
   
   



























 PD is characterized by the degeneration of dopaminer-
gic neurons and DA depletion in the striatum, the main 
biochemical feature of the disorder. The molecular mech-
anism of this pathogenetic process is still debated, even 
though the presynaptic and aggregation-prone protein 
α-syn might play a major role  [6, 7, 11] .
 We have added evidence of the protective role of DJ-1 
against dopaminergic degeneration, also caused by 
α-syn, starting from in vitro models. The importance of 
DJ-1 for PD is first of all supported by genetic studies 
linking DJ-1 loss of function to the early-onset form of 
the disease. In agreement with this, we found that DJ-1 
downregulation seems involved in the toxicity caused by 
α-syn. We had already drawn a similar conclusion in oth-
er models  [45] , but the present study makes this evidence 
firmer thanks to the observation of the increased vulner-
ability to TAT-α-syn toxicity of DJ-1 (–/–) mesencephal-
ic neurons. Recently, others have highlighted the in-
 Fig. 4. TAT-α-syn (A30P) induces a decrease in the DA level that is 
greater in DJ-1 (–/–) mice.  a Immunohistochemistry to detect 
TAT-α-syn (A30P) in the mouse brain. The presence of the recom-
binant protein (2.5 μg) was assessed by 6XHis-tag reactivity 10 days 
after injection. The arrow points to the injection site (striatum). 
 b ,  c  C57BL/6 mice were lesioned with TAT-α-syn (A30P; 0.05, 0.5 
or 2.5 μg) to induce dopaminergic cell loss and DA depletion. To 
verify the toxic effect, the striatal DA level ( b ) and 5-HT level ( c ) 
were measured by HPLC 10 days after the lesion.  * *  p < 0.01,  * * *  p < 
0.001, 1-way ANOVA and Tukey’s post hoc test (6 mice/group). 
Results are expressed as micrograms per gram of wet weight of stri-
atum.  d Immunohistochemistry to assess TH reactivity in C57BL/6 
mice in the substantia nigra after the injection of TAT-GFP or 
TAT-α-syn (A30P). The dotted oval highlights the substantia nigra 
portion with dopaminergic degeneration after TAT-α-syn (A30P). 
The vertical dashed lines separate the two hemispheres. The treated 
hemisphere is the one with the label, and the contralateral one was 
used as control.  e Quantification of TH-positive neuron (TH+) 
number in the substantia nigra of the mice receiving the treatment 
described in  d . Results are shown as direct count number.  * *  p < 
0.01, 1-way ANOVA and Tukey’s post hoc test (3 mice/group). 
 f  DJ-1 (–/–) mouse striatal DA levels after TAT-α-syn (A30P) .  Mice 
were injected with TAT-α-syn (A30P; 2.5 μg) and euthanized after 
10 days. The vehicle group received the same volume of hypotonic 
PBS.  * *  p < 0.01 versus C57BL/6 treated with TAT-α-syn (A30P), 
2-way ANOVA and Tukey’s post hoc test (6 mice/group). Results 
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volvement of DJ-1 in neuroprotection in neuron/astro-
cyte cocultures  [46] .
 An independent confirmation of a relation between 
DJ-1 and α-syn comes from our experiments with DJ-1 
silencing in PC12/TetOn cells, where DJ-1 downregula-
tion triggered the toxicity due to α-syn overproduction 
and aggregation. The fact that the mutated form A30P 
only becomes deleterious with DJ-1 silencing probably 
depends on the fact that the mutation enhances the α-syn 
aggregation rate, so in this case the reduction of DJ-1 by 
siRNA is sufficient to unmask toxicity. Instead, in the case 
of α-syn (WT), DJ-1 reduction alone was probably not 
enough to trigger toxicity, also considering that PC12/
TetOn cells have efficient alternative mechanisms for 
coping with α-syn aggregation (for instance, macroau-
tophagy and the proteasome)  [37] .
 The in vivo results suggest some discordant data on the 
role of DJ-1 in counteracting dopaminergic degenera-
tion. In fact, while a protective effect of DJ-1 against 
MPTP, 6-OHDA or MG132 was reported  [47, 48] , 
Ramsey et al.  [49] developed a mouse strain overexpress-
ing a mutated form of the α-syn gene (A53T pathogenet-
ic mutation) on a DJ-1 null background whose phenotype 
was not worsened by the lack of DJ-1. It is possible that 
our acute model of TAT-α-syn toxicity may have been 
more aggressive, thus able to highlight DJ-1’s neuropro-
tective role, while the earlier mouse model might have 
developed compensatory mechanisms for controlling 
α-syn toxicity in the absence of DJ-1. It should be noticed 
that our in vivo model of acute TAT-α-syn toxicity offers 
an easy experimental system, leading to selective dopami-
nergic degeneration, confirmed by the lack of 5-HT de-
pletion in the TAT-α-syn (A30P)-treated mice. This do-
paminergic loss was also observed in a TAT-α-syn (A30P) 
rat model of PD, where it paralleled a time-dependent 
impairment in motor function  [50] . In agreement with 
our model, the possibility of acute induction of α-syn tox-
icity by intrastriatal injection leading to a PD-like pheno-
type was also reported, even in the absence of a transloca-
tion domain in the recombinant protein  [51] .
 The exact molecular mechanisms by which DJ-1 
achieves neuroprotection needs to be further investigat-
ed, and might be both direct and indirect. For instance, 
we had found that DJ-1 was able to positively upregulate 
the chaperone protein Hsp70  [45] , which was reported to 
support neuroprotection against α-syn toxicity and sev-
eral other PD-linked stressors  [52, 53] .
 A second possibility involves the evidence that TAT-
DJ-1 treatment led to an increase in TH-positive neurons. 
This agrees with the literature suggesting a direct effect of 
DJ-1 on TH transcription  [54] . However, further experi-
ments are required to clarify the neuroprotective path-
ways sparked off by DJ-1 and whether its protective ac-
tion towards the dopaminergic system is in the substantia 
nigra or striatum.
 In summary, our results reinforce DJ-1 as a positive 
regulator of the dopaminergic system, contributing to 
our understanding of the mechanism leading to PD in the 
presence of DJ-1 failure that makes dopaminergic neu-
rons more susceptible to oxidative stress or α-syn toxicity.
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